Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients
Background Some sarcomas respond to immune checkpoint inhibition, but predictive biomarkers are unknown. We analyzed tumor DNA methylation profiles in relation to immunological parameters and response to anti-programmed cell death 1 (anti-PD-1) immune checkpoint inhibitor (ICI) therapy in patients w...
Main Authors: | Matthias Preusser, Leonhard Müllauer, Anna S Berghoff, Sebastian Bauer, Gerwin Heller, Thomas Brodowicz, Wolfgang Lamm, Katharina Feldmann, Angelika M Starzer, Rainer Hamacher, Erwin Tomasich, Teresa Hatziioannou, Stefan Traint, Iris M Noebauer-Huhmann, Julia Furtner, Gabriele Amann, Hans-Ulrich Schildhaus |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-03-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/9/3/e001458.full |
Similar Items
-
New emerging targets in cancer immunotherapy: CD27 (TNFRSF7)
by: Anna S. Berghoff, et al.
Published: (2019-06-01) -
Case Report of Suspected Rhabdomyolysis during Treatment with Trabectedin in a Patient with Metastatic Leiomyosarcoma
by: W. Lamm, et al.
Published: (2010-12-01) -
Molecular Pathology of Cancer: The Past, the Present, and the Future
by: Leonhard Müllauer
Published: (2021-07-01) -
Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab
by: Elisabeth Sophie Bergen, et al.
Published: (2021-04-01) -
Checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy
by: E.B. Cone, et al.
Published: (2020-07-01)